- Home
- KFS vs ZURA Comparison
KFS vs ZURA Comparison
Compare KFS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KFS | ZURA |
|---|---|---|
| Founded | 1989 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.8M | 407.0M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | KFS | ZURA |
|---|---|---|
| Price | $12.23 | $6.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 74.5K | ★ 779.6K |
| Earning Date | 03-16-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $128,567,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.31 | N/A |
| 52 Week Low | $7.06 | $0.97 |
| 52 Week High | $16.80 | $6.88 |
Technical Indicators
Market Signals| Indicator | KFS | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 55.28 |
| Support Level | $13.18 | $5.59 |
| Resistance Level | $13.27 | $6.88 |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 1.28 | 43.66 |
Price Performance
Historical ComparisonAbout KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.